SPRINGFIELD, Mass. (WWLP) – Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Officials investigate rare ...

The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the ...

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

Investigators tracked 38 immunocompromised individuals between the ages 64 and 72, looking at their responses to the two available RSV shots: Arexvy and Abrysvo. The report showed that there was ...

Arexvy contains an adjuvant while Abrysvo does not. "When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the ...

In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks -- with 61% of ...

Arexvy contains an adjuvant while Abrysvo does not. “When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the ...

Pfizer’s PFE RSV vaccine, Abrysvo, was launched to help protect older adults as well as infants through maternal immunization in the United States as well as in the EU in 2023. PFE’s Abrysvo ...

Meanwhile, Brazil's National Health Surveillance Agency Anvisa has greenlighted the use of Pfizer's Abrysvo vaccine that prevents bronchiolitis in babies, which must be administered to mothers ...

Pfizer’s Abrysvo will also succeed during the forecast period with sales reaching $2.9bn in its peak year in 2025. Companies such as Pfizer, Sanofi, GSK, and AstraZeneca are expected to become ...